AYX 1

Drug Profile

AYX 1

Alternative Names: AYX-1

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Adynxx
  • Class Analgesics; Oligonucleotides
  • Mechanism of Action Early growth response protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain

Most Recent Events

  • 12 May 2017 AYX 1 is still in phase II trials for Postoperative pain and Chronic pain (Prevention) in USA (Intrathecal) (Adynxx website, May 2017)
  • 01 Feb 2017 Adynxx initiates a phase II trial for Postoperative and Chronic pain (Prevention) in USA (Intrathecal) (NCT02807428)
  • 17 Jun 2016 Adynxx plans a phase II trial for Postoperative pain (Prevention) in USA (Intrathecal) (NCT02807428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top